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Screening for chronic kidney disease is recommended in
people at high risk, but data on the independent and
combined associations of estimated glomerular filtration rate
(eGFR) and albuminuria with all-cause and cardiovascular
mortality are limited. To clarify this, we performed a
collaborative meta-analysis of 10 cohorts with 266,975
patients selected because of increased risk for chronic kidney
disease, defined as a history of hypertension, diabetes, or
cardiovascular disease. Risk for all-cause mortality was not
associated with eGFR between 60–105ml/min per 1.73m2,
but increased at lower levels. Hazard ratios at eGFRs of 60,
45, and 15ml/min per 1.73m2 were 1.03, 1.38 and 3.11,
respectively, compared to an eGFR of 95, after adjustment for
albuminuria and cardiovascular risk factors. Log albuminuria
was linearly associated with log risk for all-cause mortality
without thresholds. Adjusted hazard ratios at albumin-to-
creatinine ratios of 10, 30 and 300mg/g were 1.08, 1.38, and
2.16, respectively compared to a ratio of five. Albuminuria and
eGFR were multiplicatively associated with all-cause mortality,
without evidence for interaction. Similar associations were
observed for cardiovascular mortality. Findings in cohorts
with dipstick data were generally comparable to those in
cohorts measuring albumin-to-creatinine ratios. Thus, lower
eGFR and higher albuminuria are risk factors for all-cause and
cardiovascular mortality in high-risk populations,
independent of each other and of cardiovascular risk factors.
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The definition and classification of chronic kidney disease
was proposed by Kidney Disease Outcomes Quality Initiative
(KDOQI) in 2002, and endorsed by Kidney Disease
Improving Global Outcomes (KDIGO) in 2004.1–3 Wide-
spread implementation of the definition and classification
has promoted increased attention to chronic kidney disease
in clinical practice, research, and public health.4 It has also
generated substantial debate about the appropriateness of
recommending the same glomerular filtration rate (GFR)
thresholds for people of all ages, the optimal level of
albuminuria as a marker of kidney damage, and about the
value of the 5-stage classification system based on estimated
GFR (eGFR) without consideration of albuminuria.5–8
In October 2009, KDIGO sponsored a Controversies
Conference to examine the validity of the existing system as
well as to evaluate proposed alternatives.9 The report of the
Consensus Conference is included in this issue of Kidney
International.10 As part of the process, the CKD Prognosis
Collaboration was formed to undertake a comprehensive
analysis of mortality and kidney outcomes according to
estimated GFR and albuminuria, to answer key questions
underlying the debate.
This paper is the second in a series of four papers to report
the results of collaborative meta-analyses undertaken by the
CKD Prognosis Consortium. The first paper in this series
deals with all-cause and cardiovascular mortality in general
population cohorts.11 The present report describes all-cause
and cardiovascular mortality in cohorts at high risk for chronic
kidney disease. Other manuscripts report kidney outcomes
from general population and high-risk cohorts,12 and mortality
and kidney outcomes in chronic kidney disease cohorts.13
Chronic kidney disease is now recognized as a risk factor
for all-cause and cardiovascular mortality.14 Our meta-
analysis of 21 general population cohorts showed the
independent and joint associations of reduced estimated
GFR and higher levels of albuminuria on these outcomes.11
http://www.kidney-international.org o r ig ina l a r t i c l e
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Presently, screening for chronic kidney disease is recom-
mended in people at high risk for chronic kidney disease
including patients with cardiovascular disease risk factors.4
However, the associations between eGFR and albuminuria
with mortality may differ in high-risk populations as
compared with the general population. As a comprehensive
analysis of the associations between eGFR and albuminuria
with all-cause and cardiovascular mortality in high-risk
populations has not been reported, we studied these
associations in a collaborative meta-analysis. A priori we
hypothesized that both eGFR and albuminuria would be
associated with these outcomes, independent of traditional
cardiovascular risk factors and independent of each other,
and despite inclusion of diverse study populations.
RESULTS
Study characteristics
Of 10 high-risk cohorts (266,975 subjects), 6 had data on
albumin-to-creatinine ratio (117,500 subjects) and 4 on
dipstick proteinuria (149,475 subjects) (Table 1). Acronyms
and abbreviations for studies included in the current report
are given in Supplementary Table S1 online. By definition,
the study participants have a high prevalence of cardiovas-
cular disease risk factors. The characteristics of the dipstick
cohorts are, in general, comparable to those of the albumin-
to-creatinine ratio cohorts, with the albumin-to-creatinine
ratio cohorts having a higher percentage of males and
subjects with diabetes and a history of cardiovascular disease,
and a lower percentage of Blacks. In the cohorts with
information on albumin-to-creatinine ratio, there were 8706
all-cause deaths and 3171 cardiovascular disease deaths
during follow-up. In the subjects with dipstick data, these
figures are 7303 and 2485, respectively. A total of 36.7% of
the subjects in the pooled study population with measure-
ments of albumin-to-creatinine ratio had chronic kidney
disease according to the current definition (eGFRo60ml/min
per 1.73m2 or albumin-to-creatinine ratio X30mg/g)
(Supplementary Tables S2 and S3 online). This subgroup
accounted for 58.6% of all-cause mortality events (Supple-
mentary Table S4 online) and 59.4% of cardiovascular
mortality events (Supplementary Table S5 online). Data on
cardiovascular mortality were available in only two of the
dipstick cohorts, which differed greatly in sample size and
duration of follow-up.
Independent continuous associations of eGFR and
albuminuria with mortality risk
Pooled adjusted hazard ratios of all-cause mortality and
cardiovascular mortality according to eGFR and albumin-
to-creatinine ratio are shown in Figure 1. The association
between eGFR and relative risk for all-cause mortality and
cardiovascular mortality was relatively constant between
60 and 105ml/min per 1.73m2, and steadily increased at
eGFR below 60ml/min per 1.73m2 (Figure 1, left panels).
For all-cause mortality, adjusted hazard ratios at eGFR 60,
45, and 15ml/min per 1.73m2 were 1.03 (0.81–1.33), 1.38
(1.15–1.65), and 3.11 (2.26–4.27), respectively, whereas for
cardiovascular mortality, the adjusted hazard ratios were 1.11
(0.93–1.32), 1.73 (1.49–2.00), and 3.08 (1.89–5.01), respec-
tively. The pattern for all-cause mortality was comparable in
the dipstick cohorts (Supplementary Figure S1 online),
except there was a tendency for a U-shaped relationship
Table 1 | Characteristics of included studies
N
Age
(year)
Male
(%)
Black
(%)
CVD
(%)
HT
(%)
HC
(%)
DM
(%)
Smoking
(%)
eGFR
(ml/min per 1.73m2)
ACR
(mg/g)
FU
(Year)
ACM
(n)
CVM
(N)
Cohorts with ACR data
ADVANCE 11,140 65.8 57.5 NA 32.2 82.2 33.0 100 15.1 78.2 15.9 4.8 1031 542
AKDN 67,406 55.8 56.8 NA 5.0 46.8 NA 49.0 NA 76.8 11.1 2.3 2371 —
ONTARGET 25,620 66.4 73.3 2.5 92 NA* NA* 37.5 12.6 73.6 52.2 4.5 3068 1821
Pima 6341 26.4 45.4 0 NA 12.9 4.2 20.4 27.8 14.4 11.9 13.5 1083 170
TRANSCEND 5926 66.9 57 1.8 92.5 NA* NA* 35.7 9.8 71.7 25.3 4.6 713 450
ZODIAC 1067 67.9 43.4 0 34.9 83.3 40 100 18.6 63.8 19.6 7.8 440 188
Total 117,500 8706 3171
Weighted mean 58.0 59.2 1.9 32.7 49.3 23.6 49.6 14.9 79.5 21.4 3.8
Cohorts with dipstick data
CARE 4098 58.6 86.2 3.2 100 82.9 79.0 14.2 16.1 71.9 — 4.8 371 211
KEEP 92,316 54.8 31.7 31.3 13.0 57.3 23.0 30.5 11.1 81.2 — 2.4 568 —
KP Hawaii 40,210 59.0 50.4 NA 17.0 NA NA 48.0 13.6 71.5 — 2.4 1706 —
MRFIT 12,851 46.2 100 7.2 0.0 62.3 57.1 3.1 63.7 79.7 — 21.6 4658 2274
Total 149,475 7303 2485
Weighted mean 55.3 44.1 27.4 15.3 58.8 29.1 32.4 16.4 78.2 — 4.1
Abbreviations: ACM, all-cause mortality; ACR, albumin-to-creatinine ratio; CVD, cardiovascular disease; CVM, cardiovascular mortality; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; FU, duration of follow-up; HC, hypercholesterolemia; HT, hypertension; NA, not available.
NA* in ONTARGET and TRANSCEND, respectively, a history of hypertension was reported by 69 and 76%, and statin use by 62 and 55%.
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with significantly decreased risk at eGFR 75ml/min per
1.73m2 (hazard ratio 0.83 (0.77–0.91)) and a significantly
increased risk at eGFR below 45ml/min per 1.73m2 (hazard
ratio at 15ml/min per 1.73m2 1.93 (1.46–2.56)).
In contrast, the relationship of albumin-to-creatinine ratio
to the relative risk of all-cause mortality and cardiovascular
mortality was monotonic with log hazard ratios increasing
linearly with increasing log albumin-to-creatinine ratio,
without threshold effects (Figure 1, right panels). As
compared with an albumin-to-creatinine ratio of 5mg/g,
hazard ratios for all-cause mortality at albumin-to-creatinine
ratios of 10, 30, and 300mg/g were 1.08 (1.01–1.16), 1.38
(1.23–1.56), and 2.16 (1.99–2.35), respectively, and for
cardiovascular mortality 1.13 (1.07–1.20), 1.55 (1.30–1.86),
and 2.59 (1.95–3.44), respectively.
Interactions
The interaction between eGFR and albuminuria was
significant for all-cause mortality in only 4 of 10 cohorts,
and for cardiovascular mortality in only 1 of 7 cohorts
(Supplementary Table S6 online). Significant interaction
between eGFR and age was found in 3 of 10 cohorts for all-
cause mortality, and in 2 out of 7 cohorts for cardiovascular
mortality (Supplementary Table S6 online).
Joint associations of eGFR and albuminuria with mortality
risk in the overall groups
Table 2 shows unadjusted incidence rates of all-cause and
cardiovascular mortality for cohorts with albumin-to-creati-
nine ratio data. Pooled hazard ratios for all-cause mortality
and cardiovascular mortality in the 28 categories of eGFR
and albuminuria show that a higher albumin-to-creatinine
ratio is associated with a higher risk across all levels of eGFR
and a lower eGFR is associated with a higher risk across
all levels of albumin-to-creatinine ratio, indicating multi-
plicative independence for all-cause mortality and cardio-
vascular mortality (Table 3). At severely reduced eGFR values
(15–29ml/min per 1.73m2), the risk associated with higher
albuminuria was slightly attenuated. The hazard ratios
for all-cause mortality were significantly increased in all
eGFR categories with an albumin-to-creatinine ratio
X30mg/g, whereas the hazard ratios for lower eGFR at an
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Figure 1 |Pooled adjusted hazard ratios (95% confidence interval) for all-cause (upper panels) and cardiovascular
(lower panels) mortality in high-risk cohorts with albumin-to-creatinine ratio data, according to spline eGFR (left panels)
and albumin-to-creatinine ratio (right panels), adjusted for each other and for age, sex, race, cardiovascular disease history,
systolic blood pressure, diabetes, smoking, and total cholesterol (continuous analyses). Reference categories are eGFR
95ml/min per 1.73m2 and albumin-to-creatinine ratio 5mg/g, respectively. Dots represent statistical significance, triangles represent
non-significance, and shaded areas are 95% confidence interval. ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate;
HR, hazard ratio.
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albumin-to-creatinine ratio o30mg/g were significantly
increased only for eGFR categories o45ml/min per
1.73m2. In contrast, the hazard ratios for cardiovascular
mortality were significantly increased in all albumin-to-
creatinine ratio X10mg/g categories, even when eGFR was
460ml/min per 1.73m2 and for all eGFR o60ml/min per
1.73m2 categories, even when the albumin-to-creatinine ratio
was o10mg/g.
For cohorts with dipstick data, unadjusted incidence rates
for all-cause and cardiovascular mortality are shown in
Table 4, and pooled hazard ratios for these end points in
Table 5. This latter table shows that pooled hazard ratios
for all-cause mortality were similarly increased for a higher
dipstick category across all eGFR levels and for a lower eGFR
across all dipstick categories. However, because of the
U-shaped relationship, these hazard ratios were significantly
higher than the reference group only at an eGFR level of
30–45ml/min per 1.73m2 and below, and hazard ratios
were not significantly increased in the eGFR 45–59ml/min
per 1.73m2 category with a negative or trace positive
dipstick test.
Figure 2 shows the continuous analyses (allowing inter-
action) of the hazard ratios of eGFR and albuminuria for
all-cause mortality and cardiovascular mortality of cohorts
with albumin-to-creatinine ratio and dipstick data. These
figures suggest that eGFR and albuminuria are independently
associated with all-cause mortality and cardiovascular mortal-
ity, with a tendency towards a weaker association between
albumin-to-creatinine ratio and these outcomes at severely
reduced eGFR values. The two cohorts with dipstick data
that reported on cardiovascular mortality included very few
persons with lower eGFR. Interpretation of these data is
therefore difficult.
Joint associations of eGFR and albuminuria with mortality
risk per age group
The overall incidence rates for all-cause mortality and
cardiovascular mortality were four- and twofold higher,
Table 2 | Unadjusted incidence rates (per 1000 patient-years)
for ACM and cardiovascular mortality in the high-risk cohorts
with ACR ratio data
ACR (mg/g)
o10 10–29 30–299 X300 All
ACR
eGFR (ml/min per 1.73m2)
4105 11.7 10.8 13.0 26.8 12.4
90–104 9.4 11.9 16.8 26.5 11.9
75–89 9.4 11.5 20.9 32.2 12.5
60–74 11.1 17.0 26.2 42.9 16.6
45–59 19.6 27.4 43.0 65.9 30.1
30–44 37.1 48.7 68.7 84.8 56.6
15–29 105.8 105.4 118.3 123.8 112.0
All 12.4 17.6 29.8 54.3 19.2
Cardiovascular mortality
eGFR (ml/min per 1.73m2)
4105 8.9 10.0 12.6 19.4 10.3
90–104 8.2 11.5 14.1 29.9 10.4
75–89 8.9 10.6 16.0 40.0 11.0
60–74 9.3 12.9 19.2 37.3 12.4
45–59 14.5 20.4 26.3 46.3 19.8
30–44 27.5 35.6 45.0 66.1 38.6
15–29 45.7 58.3 68.7 76.2 61.7
All 10.5 14.4 20.8 44.4 14.4
Abbreviations: ACM, all-cause mortality; ACR, albumin-to-creatinine ratio; eGFR,
estimated glomerular filtration rate.
Shaded areas make up the combined reference groups.
Table 3 | Pooled adjusted hazard ratios (95% CI) for ACM and cardiovascular mortality in the high-risk cohorts with ACR data
ACR (mg/g)
o10 10–29 30–299 X300 All
ACM
eGFR (ml/min per 1.73m2)
4105 1.26 (0.97–1.64) 1.31 (1.07–1.60) 1.51 (1.23–1.84) 2.97 (2.19–4.04) 1.10 (0.96–1.26)
90–104 Ref 1.26 (1.05–1.51) 1.63 (1.37–1.95) 2.72 (2.08–3.56) Ref
75–89 0.88 (0.70–1.11) 1.12 (0.85–1.48) 1.58 (1.36–1.84) 2.91 (2.28–3.73) 0.93 (0.77–1.12)
60–74 0.82 (0.64–1.05) 1.18 (0.89–1.56) 1.63 (1.28–2.07) 2.67 (1.76–4.04) 0.98 (0.75–1.27)
45–59 1.16 (0.77–1.73) 1.39 (0.97–1.98) 1.96 (1.57–2.43) 3.58 (2.54–5.05) 1.37 (1.00–1.88)
30–44 1.54 (1.11–2.13) 2.06 (1.42–2.97) 2.84 (1.98–4.06) 3.99 (2.73–5.83) 2.01 (1.47–2.75)
15–29 2.73 (1.87–3.97) 3.52 (2.18–5.69) 3.73 (2.90–4.80) 5.43 (3.94–7.49) 3.21 (2.58–4.01)
All Ref 1.28 (1.17–1.39) 1.79 (1.60–2.00) 3.29 (3.04–3.56)
Cardiovascular mortality
eGFR (ml/min per 1.73m2)
4105 1.20 (0.89–1.62) 1.62 (1.10–2.39) 2.04 (1.40–2.95) 3.55 (1.80–7.01) 1.03 (0.86–1.24)
90–104 Ref 1.56 (1.12–2.17) 1.95 (1.44–2.65) 4.12 (2.50–6.77) Ref
75–89 1.02 (0.82–1.26) 1.34 (1.03–1.76) 1.82 (1.42–2.34) 4.76 (3.32–6.81) 0.98 (0.85–1.13)
60–74 1.00 (0.81–1.23) 1.54 (1.16–2.04) 2.01 (1.55–2.59) 4.00 (2.83–5.66) 1.01 (0.80–1.28)
45–59 1.42 (1.14–1.77) 2.06 (1.60–2.66) 2.56 (2.03–3.22) 5.58 (3.19–9.79) 1.63 (1.22–2.18)
30–44 2.27 (1.72–3.01) 3.74 (2.06–6.78) 3.95 (3.02–5.18) 6.00 (4.40–8.18) 2.50 (2.10–2.97)
15–29 3.93 (2.10–7.35) 5.60 (2.34–13.43) 6.06 (3.89–9.45) 7.21 (4.33–11.99) 3.98 (3.02–5.24)
All Ref 1.46 (1.32–1.62) 2.09 (1.73–2.53) 4.02 (3.50–4.62)
Abbreviations: ACM, all-cause mortality; ACR, albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; Ref, reference cell.
Shaded areas are the reference groups.
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respectively, in the subgroup of subjects with age X65 years
compared with the subgroup with age o65 years (Supple-
mentary Tables S7 and S8 online). For albumin-to-creatinine
ratio cohorts, pooled hazard ratios for all-cause mortality and
cardiovascular mortality of the 28 categories of eGFR and
albumin-to-creatinine ratio according to age group are
shown in Tables 6 and 7, respectively. For higher albumin-
to-creatinine ratios, younger and older subjects showed a
similar pattern for all-cause mortality and cardiovascular
mortality. However, the patterns for eGFR were less steep
among older subjects when compared with younger subjects.
For all-cause mortality in dipstick cohorts, these patterns
were generally similar to those in albumin-to-creatinine ratio
cohorts (Table 8). Only one of the two dipstick cohorts that
reported on cardiovascular mortality included subjects X65
years of age. For this reason, no data are shown for risk for
cardiovascular mortality according to age group in dipstick
cohorts.
Heterogeneity
For the categorical analyses, we found modest but statistically
significant heterogeneity in pooled adjusted hazard ratios
within some eGFR albuminuria categories. For all-cause
mortality, heterogeneity was significant in 9 of 28 categories
in the albumin-to-creatinine ratio cohorts, and in 6 of 28
categories in the dipstick cohorts (Supplementary Table S9
online). For cardiovascular mortality, heterogeneity was
significant in 2 of 28 categories in the albumin-to-creatinine
ratio cohorts (Supplementary Table S10 online). Qualita-
tively, however, the direction of the associations was the same
in all cohorts—increased risk with lower eGFR categories and
with higher albuminuria categories. Significant heterogeneity
was, in nearly all cases, limited to the lowest eGFR and the
highest albuminuria categories. Significant heterogeneity for
all-cause mortality and cardiovascular mortality was observed
in only very few of the eGFR albuminuria categories of most
Table 4 | Unadjusted incidence rates (per 1000 patient-years)
for ACM and cardiovascular mortality in the high-risk cohorts
with dipstick data
ACR ratio (mg/g)
o10 10–29 30–299 X300 All
ACM
eGFR (ml/min per 1.73m2)
4105 3.8 2.0 6.7 8.7 3.8
90–104 6.0 4.2 8.2 24.3 6.1
75–89 6.9 6.8 10.9 28.3 7.8
60–74 8.0 9.1 18.2 32.5 10.5
45–59 10.1 14.5 30.7 52.9 18.0
30–44 18.3 26.2 40.8 69.9 35.9
15–29 32.4 55.1 49.8 113.2 75.5
All 7.7 8.5 20.5 53.3 11.9
Cardiovascular mortality
eGFR (ml/min per 1.73m2)
4105 7.1 9.2 23.8 9.2 8.2
90–104 8.2 9.9 19.1 17.7 8.9
75–89 7.2 8.2 8.5 25.6 7.6
60–74 8.6 10.8 12.9 22.3 9.3
45–59 10.1 10.1 35.3 21.8 12.7
30–44 4.6 20.7 27.5 48.1 16.3
15–29 a a a a a
All 8.0 9.6 15.9 23.3 8.8
Abbreviations: ACM, all-cause mortality; ACR, albumin-to-creatinine ratio; eGFR,
estimated glomerular filtration rate.
Shaded areas make up the combined reference groups.
aInsufficient number of events for reliable estimates.
Table 5 | Pooled adjusted hazard ratios (95% CI) for ACM and cardiovascular mortality in high-risk cohorts with dipstick data
Dipstick (classes)
Negative Trace 1+ X2+ All
ACM
eGFR (ml/min per 1.73m2)
4105 1.08 (0.91–1.27) 1.16 (0.69–1.97) 2.10 (1.33–3.32) 1.86 (0.63–5.46) 1.06 (0.93–1.22)
90–104 Ref 1.09 (0.90–1.32) 1.63 (1.20–2.21) 3.86 (1.44–10.36) Ref
75–89 0.82 (0.75–0.90) 1.02 (0.86–1.20) 1.35 (0.88–2.05) 3.22 (1.59–6.52) 0.85 (0.76–0.95)
60–74 0.81 (0.73–0.89) 0.93 (0.79–1.11) 1.41 (0.85–2.35) 2.29 (1.32–3.98) 0.85 (0.74–0.97)
45–59 0.88 (0.75–1.03) 1.05 (0.82–1.36) 2.25 (1.55–3.25) 2.40 (1.13–5.12) 1.07 (0.84–1.35)
30–44 1.18 (0.68–2.06) 1.87 (1.30–2.68) 2.51 (1.78–3.54) 5.50 (3.56–8.50) 1.69 (1.34–2.12)
15–29 3.12 (1.53–6.37) 4.25 (2.11–8.58) 3.49 (2.26–5.41) 7.14 (4.64–10.99) 3.40 (2.70–4.29)
All Ref 1.24 (1.09–1.41) 1.93 (1.38–2.70) 3.48 (1.75–6.92)
Cardiovascular mortality
eGFR (ml/min per 1.73m2)
4105 0.96 (0.73–1.26) 1.07 (0.62–1.83) 3.05 (0.60–15.40) 1.18 (0.29–4.75) 0.96 (0.76–1.21)
90–104 Ref 1.10 (0.81–1.50) 2.07 (1.24–3.46) 2.28 (1.07–4.86) Ref
75–89 0.87 (0.75–1.00) 1.03 (0.85–1.26) 1.03 (0.72–1.48) 2.82 (1.03–7.70) 0.86 (0.76–0.98)
60–74 0.86 (0.75–1.00) 1.05 (0.72–1.54) 1.29 (0.91–1.82) 1.91 (0.96–3.79) 0.86 (0.76–0.98)
45–59 0.89 (0.79–1.15) 1.04 (0.65–1.66) 2.70 (1.29–5.68) 1.62 (0.80–3.31) 0.94 (0.76–1.16)
30–44 0.55 (0.13–2.31) 1.07 (0.23–5.05) 3.06 (0.81–11.56) 3.45 (1.01–11.76) 1.07 (0.51–2.22)
15–29 a a a a a
All Ref 1.15 (1.03–1.29) 1.57 (1.27–1.93) 2.30 (1.52–3.50)
Abbreviations: ACM, all-cause mortality; CI, confidence interval; eGFR, estimated glomerular filtration rate; Ref, reference cell.
Shaded areas are the reference groups.
aInsufficient number of events for reliable estimates.
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clinical interest (eGFR of 45–60ml/min per 1.73m2 and
albumin-to-creatinine ratio 30–300mg/g or dipstick 1þ ).
For the continuous analyses, forest plots are shown for the
eGFR and albumin-to-creatinine ratio knots of most clinical
interest (eGFR 45ml/min per 1.73m2 and albumin-to-
creatinine ratio 30mg/g) (Supplementary Figure S2 online).
For all-cause mortality, significant heterogeneity was found,
whereas for cardiovascular mortality, this was not observed.
Meta-regression analysis was conducted for all-cause mor-
tality and cardiovascular mortality at these knots to explore
sources of heterogeneity, taking into account all variables
listed in Table 1. Only two (near) significant associations
were found: duration of follow-up and baseline eGFR was
negatively associated with relative risk for all-cause mortality
at an albumin-to-creatinine ratio 30mg/g when compared
with 5mg/g (Supplementary Figure S3 online). However, both
meta-regressions are, for a large part, explained by 1 outlier
(Pima Indian study), characterized by a high baseline eGFR
(144ml/min per 1.73m2). Without this outlier, no significant
associations were noted (P¼ 0.33 and P¼ 0.20, respectively).
DISCUSSION
In this collaborative meta-analysis of 10 high-risk cohorts,
including 267,275 subjects, we found that a lower eGFR and a
higher albuminuria were associated with a higher risk for all-
cause mortality, independent of each other and independent
of traditional cardiovascular disease risk factors. A similar
association of eGFR and albuminuria was found with the risk
for cardiovascular mortality.
The risk for all-cause mortality and cardiovascular mortality
based on eGFR and albuminuria has been reported in a limited
number of high-risk cohorts.15–17 The current meta-analysis
confirms these studies and extends the generalizability of
these data to other populations worldwide. Furthermore, our
collaborative meta-analysis includes 16,702 all-cause mortality
and 5656 cardiovascular mortality events, substantially more
than the number of events in reports of individual studies,
allowing more precise evaluation of the independent and joint
associations of these measures with these outcomes.
We observed an exponential increase in risk for both all-
cause mortality and cardiovascular mortality risk at low
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Figure 2 |Pooled adjusted hazard ratios (95% confidence interval) for all-cause (left panels) and cardiovascular (right panels)
mortality according to eGFR and albuminuria based on continuous models with eGFR (splines), albuminuria (log-linear albumin-to-
creatinine ratio or categorical dipstick), and their interaction terms. Upper panels show data for high-risk cohorts with albumin-to-
creatinine ratio data, and lower panels for high-risk cohorts with dipstick data. Hazard ratios are adjusted for age, sex, race, cardiovascular
disease history, systolic blood pressure, diabetes, smoking, and total cholesterol. Dots represent statistical significance, triangles represent
non-significance, and shaded areas are 95% confidence interval. In this figure, albuminuria is treated categorically. Black lines and blue
shading represent an albumin-to-creatinine ratio o30mg/g or dipstick negative or trace; green lines and green shading an albumin-to-
creatinine ratio 30–299mg/g or dipstick 1þ ; and red lines and red shading an albumin-to-creatinine ratio X300mg/g or dipstick X2þ .
ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
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eGFR. In the cohorts with albumin-to-creatinine ratio data,
increased hazard ratios became statistically significant around
eGFR 60ml/min per 1.73m2, and were two- and threefold
higher at eGFR 45 and 15ml/min per 1.73m2, respectively,
compared with optimal eGFR, independent of albuminuria
and potential confounders. In the cohorts with dipstick data,
we observed a U-shaped relationship, and the increased
hazard ratio with lower eGFR became significant only below
eGFR 45ml/min per 1.73m2. We also observed the U-shaped
relationship with all-cause mortality in the general popula-
tion cohorts,11 and it has been observed by others.18 This
U-shaped relationship can make it more difficult to
interpreter the eGFR threshold for increased risk. Of note,
the Modification of Diet in Renal Disease Study equation is
Table 6 | Pooled adjusted hazard ratios (95% CI) for ACM in the high-risk cohorts with ACR data, by age group
ACR (mg/g)
o10 10–29 30–299 X300 All
ACM, younger than 65 years of age
eGFR (ml/min per 1.73m2)
4105 1.43 (1.13–1.80) 1.33 (1.04–1.72) 1.45 (1.12–1.88) 3.10 (2.20–4.38) 1.12 (0.94–1.33)
90–104 Ref 1.45 (1.07–1.97) 1.58 (1.24–2.01) 2.79 (1.98–3.95) Ref
75–89 0.90 (0.69–1.19) 1.30 (0.77–2.20) 1.77 (1.31–2.38) 2.92 (2.11–4.03) 1.00 (0.76–1.32)
60–74 0.80 (0.62–1.04) 1.32 (0.88–1.97) 1.77 (1.22–2.56) 3.60 (2.48–5.21) 1.04 (0.77–1.40)
45–59 1.21 (0.79–1.84) 1.60 (1.04–2.45) 2.21 (1.41–3.46) 4.88 (3.47–6.88) 1.72 (1.10–2.69)
30–44 2.03 (1.26–3.27) 2.96 (0.88–10.03) 3.67 (1.77–7.61) 6.22 (4.54–8.51) 2.73 (1.78–4.20)
15–29 9.27 (2.92–29.45) 9.16 (4.19–20.00) 5.79 (3.03–11.08) 6.42 (4.12–10.02) 4.69 (3.42–6.42)
All Ref 1.34 (1.08–1.66) 1.73 (1.44–2.07) 3.40 (2.77–4.16)
ACM, aged 65 years or older
eGFR (ml/min per 1.73m2)
4105 1.03 (0.71–1.49) 1.30 (0.92–1.85) 1.59 (1.15–2.18) 2.54 (1.24–5.17) 0.99 (0.79–1.24)
90–104 Ref 1.09 (0.82–1.45) 1.66 (1.27–2.16) 2.62 (1.68–4.07) Ref
75–89 0.87 (0.66–1.14) 1.00 (0.74–1.36) 1.51 (1.22–1.86) 2.81 (1.86–4.26) 0.82 (0.65–1.03)
60–74 0.81 (0.60–1.09) 1.02 (0.71–1.46) 1.43 (1.03–1.99) 2.04 (1.20–3.46) 0.86 (0.67–1.09)
45–59 0.98 (0.69–1.38) 1.23 (0.80–1.90) 1.90 (1.47–2.44) 3.01 (2.22–4.09) 1.14 (0.89–1.46)
30–44 1.46 (0.98–2.17) 1.89 (1.32–2.69) 2.45 (1.62–3.69) 3.10 (2.08–4.61) 1.71 (1.27–2.31)
15–29 2.67 (1.71–4.18) 2.92 (1.77–4.82) 3.46 (2.52–4.75) 5.22 (3.36–8.10) 2.81 (2.27–3.49)
All Ref 1.31 (1.22–1.41) 1.85 (1.73–1.98) 3.18 (2.87–3.51)
Abbreviations: ACM, all-cause mortality; ACR, albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; Ref, reference cell.
Shaded areas are the reference groups.
Table 7 | Pooled adjusted hazard ratios (95% CI) for cardiovascular mortality in the high-risk cohorts with ACR data, by age
group
ACR (mg/g)
o10 10–29 30–299 X300 All
Cardiovascular cause mortality, younger than 65 years of age
eGFR (ml/min per 1.73m2)
4105 1.27 (0.84–1.94) 1.78 (0.95–3.34) 2.05 (0.89–4.71) 4.55 (1.92–10.82) 0.96 (0.74–1.24)
90–104 Ref 2.09 (0.99–4.44) 2.20 (1.35–3.59) 6.24 (3.35–11.64) Ref
75–89 1.11 (0.81–1.52) 2.06 (0.88–4.84) 2.22 (1.53–3.23) 5.35 (2.96–9.66) 1.04 (0.85–1.29)
60–74 1.00 (0.64–1.56) 1.65 (1.07–2.53) 2.72 (1.43–5.18) 6.71 (2.01–22.46) 1.11 (0.71–1.73)
45–59 1.57 (1.09–2.26) 2.83 (1.49–5.38) 3.00 (1.33–6.74) 7.48 (2.24–24.96) 2.09 (1.09–3.98)
30–44 3.06 (1.69–5.52) 9.89 (2.15–45.45) 4.55 (1.64–12.62) 9.12 (5.63–14.76) 3.26 (1.85–5.73)
15–29 13.12 (1.80–95.72) 17.52 (4.59–66.81) 13.00 (3.19–53.02) 13.60 (5.11–36.16) 6.11 (3.49–10.70)
All Ref 1.53 (1.15–2.04) 2.07 (1.60–2.68) 4.54 (3.59–5.73)
Cardiovascular mortality, aged 65 years or older
eGFR (ml/min per 1.73m2)
4105 1.22 (0.78–1.90) 1.63 (0.92–2.89) 2.38 (1.52–3.75) 5.62 (1.35–23.47) 1.21 (0.91–1.60)
90–104 Ref 1.39 (0.89–2.15) 1.83 (1.18–2.84) 2.97 (1.25–7.02) Ref
75–89 0.98 (0.73–1.32) 1.22 (0.77–1.92) 1.72 (1.23–2.40) 4.70 (2.92–7.58) 0.94 (0.74–1.19)
60–74 1.02 (0.76–1.36) 1.39 (0.95–2.02) 1.69 (1.01–2.85) 3.87 (2.55–5.90) 1.00 (0.77–1.32)
45–59 1.31 (0.91–1.91) 1.94 (1.41–2.66) 2.62 (1.94–3.55) 4.73 (3.21–6.96) 1.50 (1.24–1.82)
30–44 2.08 (1.36–3.16) 2.95 (2.02–4.33) 4.03 (2.89–5.62) 5.20 (3.41–7.92) 2.44 (1.97–3.03)
15–29 3.96 (1.99–7.87) 4.39 (1.94–9.93) 5.85 (3.53–9.68) 6.24 (3.33–11.72) 3.72 (2.67–5.19)
All Ref 1.47 (1.30–1.66) 2.07 (1.69–2.53) 3.78 (3.18–4.49)
Abbreviations: ACR, albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; Ref, reference cell.
Shaded areas are the reference groups.
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known to underestimate measured GFR at the range of GFR
X60ml/min per 1.73m2 in healthy individuals, and to have
more variability among racial groups, such as Blacks and
Pima Indians.19 Furthermore, the Modification of Diet in
Renal Disease equation overestimates measured GFR in
individuals with reduced muscle mass because of ill health,
the latter potentially contributing to the U-shaped associa-
tion of GFR with mortality.
The association of albuminuria with mortality was linear
on the log-log scale, with a 1.5- and 2.5-fold higher risk at
albumin-to-creatinine ratio 30 and 300mg/g (corresponding
to thresholds for microalbuminuria and macroalbuminuria),
respectively, compared with an optimal albumin-to-creati-
nine ratio level (5mg/g), independent of eGFR and conven-
tional cardiovascular disease risk factors. Of note, the risk for
cardiovascular mortality was statistically significant at an
albumin-to-creatinine ratio of 10mg/g compared with 5mg/g.
These findings are in agreement with previous reports that
the association of albuminuria with all-cause mortality and
cardiovascular mortality appears continuous with increased
risk at levels below 30mg/g.15,20–22 Our findings of an
increased relative risk of lower eGFR and of higher albu-
minuria were, in general, comparable for cohort studies with
data on dipstick and cohort studies with data on albumin-to-
creatinine ratio. These findings suggest that measurement of
dipstick proteinuria is useful for risk stratification, despite
being a less precise measure of albuminuria.
The statistical code that was sent to the participating
cohorts rendered output that did not permit computation of
a meta-analytic result for interactions. However, the general
pattern of a graded increase in risk with lower eGFR and
higher albuminuria was present for subjects younger as well
as older than 65 years of age. Moreover, the hazard ratios for
higher albuminuria for both all-cause mortality and
cardiovascular mortality increase to a similar extent in older
and younger subjects, and in cohorts with albumin-to-
creatinine ratio data as well as in cohorts with dipstick data.
In contrast, the pattern of higher relative hazards of a lower
eGFR for all-cause mortality and cardiovascular mortality is
less steep in the subgroups older than 65 years of age than in
those younger than 65 years of age (Tables 4 and 5). This less
steep relationship with lower eGFR may be a reflection of the
increased incidence rates for these outcomes in the older
subgroup (Supplementary Table S3 online). Similar findings
have been reported for traditional cardiovascular risk
factors.23 Of note, tests for interaction between eGFR and
age for all-cause mortality and cardiovascular mortality were
not significant in the majority of studies (Supplementary
Table S9 online).
The pattern of an increased risk for all-cause mortality and
cardiovascular mortality for both a lower eGFR and a higher
albuminuria in these high-risk cohorts is comparable to that
observed in the general population cohorts.11 This is an
important observation in the context of the recommenda-
tions for screening for chronic kidney disease. Current
recommendations limit screening to subjects at increased
risk.1–4 The similar relative risks for mortality of lower eGFR
and higher albuminuria in general population and high-risk
population cohorts suggest that the potential benefit of
detecting a case of chronic kidney disease would be similar in
both populations. However, the yield from screening would
be expected to be higher in the high-risk population because
Table 8 | Pooled adjusted hazard ratios (95% CI) for ACM in the cohorts with dipstick data, by age group
Dipstick (classes)
Negative Trace 1+ X2+ All
ACM, younger than 65 years of age
eGFR (ml/min per 1.73m2)
4105 1.06 (0.89–1.26) 1.16 (0.64–2.08) 2.09 (1.09–3.99) 1.59 (0.63–3.99) 1.07 (0.92–1.24)
90–104 Ref 1.06 (0.86–1.29) 1.55 (1.09–2.20) 3.06 (1.17–8.04) Ref
75–89 0.87 (0.56–1.35) 0.98 (0.85–1.12) 1.19 (0.93–1.53) 2.94 (1.41–6.13) 0.83 (0.72–0.97)
60–74 0.81 (0.73–0.89) 0.88 (0.76–1.02) 1.50 (0.79–2.84) 2.61 (1.24–5.49) 0.90 (0.72–1.12)
45–59 0.87 (0.73–1.04) 0.93 (0.65–1.31) 2.75 (1.10–6.87) 3.22 (1.25–8.29) 1.47 (0.83–2.59)
30–44 2.26 (0.91–5.57) 1.82 (0.79–4.20) 3.16 (1.59–6.27) 6.11 (3.34–11.18) 2.08 (1.25–3.46)
15–29 6.62 (1.54–28.44) 10.84 (1.41–83.19) 4.06 (1.58–10.44) 12.06 (5.28–27.53 6.26 (3.96–9.90)
All Ref 1.13 (1.04–1.21) 1.95 (1.26–3.01) 3.85 (1.64–9.08)
ACM, aged 65 years or older
eGFR (ml/min per 1.73m2)
4105 1.53 (0.74–3.17) 0.98 (0.36–2.69) 2.52 (0.86–7.39) 3.70 (1.02–13.46) 1.12 (0.66–1.91)
90–104 Ref 1.35 (0.74–2.46) 1.75 (0.92–3.34) 6.70 (3.02–14.87) Ref
75–89 0.79 (0.49–1.30) 1.44 (0.88–2.34) 1.97 (1.19–3.27) 4.40 (2.30–8.43) 0.91 (0.70–1.19)
60–74 0.77 (0.49–1.21) 1.11 (0.70–1.76) 1.70 (1.07–2.71) 2.62 (1.45–4.76) 0.83 (0.55–1.25)
45–59 0.93 (0.59–1.47) 1.12 (0.70–1.78) 2.05 (1.29–3.24) 2.90 (1.38–6.07) 0.90 (0.71–1.15)
30–44 1.20 (0.72–1.99) 1.74 (1.07–2.82) 2.45 (1.53–3.93) 5.30 (2.89–9.70) 1.51 (1.00–2.27)
15–29 2.57 (1.05–6.33) 3.53 (1.75–7.12) 3.03 (1.76–5.24) 5.68 (3.26–9.88) 2.58 (1.96–3.41)
All Ref 1.43 (1.24–1.64) 2.31 (2.02–2.64) 4.56 (3.18–6.54)
Abbreviations: ACM, all-cause mortality; CI, confidence interval; eGFR, estimated glomerular filtration rate; Ref, reference cell.
Shaded areas are the reference groups.
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of the higher prevalence of chronic kidney disease. Further
study of the benefit of case detection and yield of screening
for chronic kidney disease is required to inform public
health policies.
We acknowledge that this meta-analysis has limitations.
First, we did not perform a systematic literature search to
identify all potential eligible cohorts. However, study
selection was unbiased with respect to the associations of
interest, and most of the included cohorts had not reported
or investigated these associations before we performed our
pooled analysis. Selection bias is therefore unlikely. To our
knowledge, the present analysis is the largest and most
comprehensive assessment of the relationship between eGFR
and albuminuria in high-risk populations. Second, the data
analysis we used provides superior consistency of results
compared with a review of the literature, but falls short of
having a uniform study protocol and centralized laboratories
across all cohorts. Measurements of creatinine and albumi-
nuria were not comparable across all cohorts. Third, no data
could be taken into account on effects of treatment that was
started during follow-up. Therefore, it cannot be excluded
that the observed associations are influenced by the start
of specific treatments. However, if such treatment is effective
in preventing all-cause and cardiovascular mortality, as
is expected for cardiovascular disease risk reduction, then it
would be expected to lead to an underestimation of the true
relative risk of low eGFR and high albuminuria for these
outcomes. Fourth, our results showing residual statistical
heterogeneity imply that the relationships of eGFR with
all-cause mortality and of albumin-to-creatinine ratio with
all-cause mortality (and their level of statistical significance)
may differ across various subpopulations, although what
characterizes these subpopulation differences could not be
determined using meta-regression.
Strengths of our study are the large sample size and large
number of well-defined outcomes. Moreover, the consistency
of our findings in both continuous as well as categorical
analyses, in cohorts with albumin-to-creatinine ratio data as
well as in cohorts with dipstick data, with respect to both
all-cause mortality as well as to cardiovascular mortality,
shows the robustness of our findings and makes likely that
bias would not have had a major role. Finally, the simi-
larity between our present findings in high-risk cohorts
and previous findings in general population cohorts11 and
cohorts including only subjects with known chronic kidney
disease13 strengthens the validity of our findings that both
eGFR and albuminuria are independently associated with
outcome. These considerations, together with the fact that
the presently studied cohorts originate from all over the
world (Supplementary Table S1 online), suggest that the
results are generalizable to a broad population.
Altogether the relative risks in this analysis are consistent
with the current KDOQI thresholds for eGFR o60ml per
min per 1.73m2 and albumin-to-creatinine ratio X30mg/g
for the definition of chronic kidney disease as indicative of
increased mortality risk. They also suggest that the addition
of albuminuria stages in chronic kidney disease staging
independent of GFR would be helpful in predicting mortality
risk. The finding that mortality risk is substantially higher
in subjects with an eGFR 30–45 when compared with
45–60ml/min per 1.73m2 supports the proposed subdivision
of the present stage 3 chronic kidney disease into two stages.
Some have suggested age-specific thresholds, arguing that
lower eGFR at older age is a reflection of ageing24 and
associated with lower risk for adverse outcomes than at
younger age.25,26 We indeed found a less steep pattern of
relative risk of all-cause mortality with lower eGFR in older
subjects compared with younger subjects. However, absolute
mortality risk is higher in older versus younger subjects, and
relative risks for cardiovascular mortality were more similar
in older versus younger subjects. Therefore, these data do not
provide evidence for the use of age-specific eGFR thresholds
to define chronic kidney disease. In general, decisions
regarding which levels of eGFR and albuminuria to be used
for the definition and staging of chronic kidney disease and
guide clinical management should incorporate a wide range
of considerations, including not only relative risk, but also
prevalence, absolute risk, risk classification, and the cost-
effectiveness of preventive measures.
In conclusion, our data show that both albuminuria and
eGFR are associated with all-cause and cardiovascular mortality,
independent of each other and independent of cardiovascular
risk factors. These findings provide a quantitative basis for
including these two kidney measures for risk stratification, and
chronic kidney disease definition and staging.
MATERIALS AND METHODS
Study selection
Studies were identified by the planning committee and analytic
team, and by discussion between collaborators. This was enhanced
by a call for participation at the World Congress of Nephrology in
Milan, 2009, a published position statement of KDOQI and
KDIGO,9 and an announcement on the KDIGO website (http://
www.KDIGO.org). To be eligible for inclusion, studies had to meet
the following criteria: (1) prospective cohort study; (2) including
subjects referred for evaluation of chronic kidney disease risk factors
or subjects known to have at least one risk factor defined as a history
of cardiovascular disease, diabetes, hypertension, hypercholester-
olemia, or family history of cardiovascular disease; (3) information
at baseline on eGFR as well as on albuminuria; (4) at least 1000
subjects included; (5) information on mortality; and (6) a minimum
of 50 events for all-cause mortality or cardiovascular mortality. The
reason to require a minimum sample size is to ensure sufficient
outcomes in the reference cell. This process identified 12 cohorts
that met the inclusion criteria. The investigators of 10 eligible
studies were willing to participate in this meta-analysis.15–17,27–33
Study variables
In each cohort, subjects were subdivided according to eGFR and
albuminuria. GFR was estimated using the Modification of Diet in
Renal Disease Study equation.34 Each participating study was asked
to standardize their serum creatinine to isotope dilution mass
spectrometry-traceable methods, but calibration methods were not
uniform. As recommended in clinical practice guidelines,1,35–37
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albuminuria was assessed as the albumin-to-creatinine ratio. If first
morning voids were not available, spot urine samples or samples
from 24 h urine collections were used. In studies in which no
quantitative albuminuria measurements were available, data on
dipstick testing for proteinuria were collected.17,27–29
Besides eGFR and albuminuria, information on demographic
factors and cardiovascular risk factors were obtained to compare
baseline characteristics of the different cohort studies and to adjust
for confounding in multivariable models. Cardiovascular disease
history was defined as a history of myocardial infarction, bypass
grafting, percutaneous coronary intervention, heart failure, or
stroke. Hypertension was defined as systolic blood pressure
X140mmHg or diastolic blood pressure X90mmHg or use of
antihypertensive medication. Hypercholesterolemia was defined as
total cholesterol 45.0mmol/l in the case of a positive history of
cardiovascular disease and as 46.0mmol/l in the case of a negative
history of cardiovascular disease. Diabetes mellitus was defined as
fasting glucose X7.0mmol/l or non-fasting glucose X11.1mmol/l
or use of glucose-lowering drugs. Smoking habit was dichotomised
as current versus not current smoking.
Outcome measures for this meta-analysis were all-cause
mortality and cardiovascular mortality, with the latter defined as
death due to myocardial infarction, heart failure, sudden cardiac
death, or stroke. Cardiovascular mortality was chosen as a specific
cause of death, as it is the leading cause of death in individuals with
chronic kidney disease.14
Statistical analysis
Our primary objective was to evaluate the associations of eGFR and
albuminuria, independently and jointly on all-cause mortality and
cardiovascular mortality. To maximize uniformity and minimize
bias, investigators from the cohort studies were invited to
collaborate in a pooled analysis following an a priori analytic plan
using standard statistical code provided by the analytic team of the
CKD Prognosis Consortium. All analyses were conducted using
Stata version 10 or 11 (Stata Corp, College Station, TX, SAS version
9 (SAS Institute, Cary, NC), or R version 2.9.2 (R Foundation for
Statistical Computing, Vienna, Austria). All data classification was
performed separately by analytic teams at the John Hopkins
Bloomberg School of Public Health, Baltimore, USA (KM, JC, and
BCA) and the University Medical Center Groningen, Groningen, the
Netherlands (MvdV, PEdJ, and RTG), and differences were resolved
by consensus.
Some of the included cohorts consisted of participants of
randomised controlled trials.15,17,29–31 All participants in these trials
met our inclusion criteria (high risk for chronic kidney disease). Of
these cohorts, only data were used that were obtained during the
trial, thus no follow-up data beyond the duration of the actual trials
were taken into account. In multivariable regression analysis,
we adjusted for treatment allocation, enhancing generalizability of
these trial populations to the observational cohorts in our pooled
analysis.
For each study, a table was generated providing baseline study
characteristics. Cox proportional hazard models were used to
estimate the hazard ratios for all-cause mortality and cardio-
vascular mortality. These analyses were adjusted for age, sex, race,
cardiovascular disease history, smoking status, diabetes mellitus,
systolic blood pressure, and serum total cholesterol, and for
randomized controlled trials also for treatment arm. The indepen-
dent continuous association of eGFR and albuminuria with risk for
all-cause and cardiovascular mortality was evaluated after adjusting
for each other and for cardiovascular disease risk factors. eGFR and
albumin-to-creatinine ratio were modeled using linear splines with
knots at 45, 60, 75, 90, and 105ml/min per 1.73m2, and 10, 30,
and 300mg/g, respectively. eGFR 95ml/min per 1.73m2 and
an albumin-to-creatinine ratio 5mg/g were treated as the
reference points. These points were chosen, as they reflect the
anticipated low-risk groups. Interactions between eGFR and both
albuminuria and age were evaluated by likelihood-ratio tests in
individual studies, with albuminuria and age treated as continuous
variables.
For each outcome variable, information was generated for the
joint association of eGFR and albuminuria with kidney outcomes.
Eight eGFR categories were defined: o15, 15–29, 30–44, 45–59,
60–74, 75–89, 90–104, and X105ml/min per 1.73-m2. These 15ml/
min per 1.73m2 categories were chosen to correspond to current
chronic kidney disease stages 1–5, and to evaluate whether these
stages should be subdivided. For albumin-to-creatinine ratio, we
defined four categories:o10, 10–29, 30–299, andX300mg/g. These
categories were chosen to correspond to current definitions for
microalbuminuria and macroalbuminuria, and to evaluate whether
the normoalbuminuria category should be subdivided. When
information on albumin-to-creatinine ratio was lacking, we used
information on dipstick proteinuria. As it has been shown that the
majority of subjects with a dipstick trace have high-normal
albuminuria, dipstick 1þ microalbuminuria, and dipstick X2þ
macroalbuminuria,37 we defined four dipstick categories: negative,
trace, 1þ , andX2þ , respectively. A priori, the reference categories
of eGFR 90–104ml/min per 1.73m2 and an albumin-to-creatinine
ratio o10mg/g or dipstick negative were chosen, as they were
considered to represent subjects with the lowest risk. For all of the 32
eGFR albuminuria categories, information was obtained on the
distribution of subjects and the distribution of incident events. For
each study, the unadjusted incidence rate per 1000 person-years was
calculated for each category. Hazard ratios were estimated with
adjustment for the aforementioned cardiovascular risk factors. We
conducted complementary analyses where eGFR and albumin-to-
creatinine ratio were modeled continuously using the same
statistical models and adjustments. These models were parameter-
ized with eGFR of 95ml/min per 1.73m2, albumin-to-creatinine
ratio of 5mg/g or dipstick negative/trace as the reference point
(hazard ratio¼ 1.0).
Pooled unadjusted incidence rates were obtained by weighting
the individual studies by the number of subjects per category.
Pooled estimates of the adjusted hazard ratios, with 95% confidence
intervals, were obtained from random effects meta-analyses.
Heterogeneity was estimated using the w2-test for heterogeneity
and the I2 statistic.38 Meta-analyses were conducted separately for
cohorts with albumin-to-creatinine ratio data and cohorts with
dipstick data. As there were few participants (0.2%) with eGFR
o15ml/min per 1.73m2, we only report results for participants
with eGFR X15ml/min/ per 1.73m2. A priori, it was considered
that age could be an important effect modifier, and hence results
were also produced for age o65 and X65 years. As statistical
heterogeneity in the associations under study was anticipated, we
a priori defined systematic exploration of possible source hetero-
geneity. This was done by meta-regression analysis, using the
continuous analyses with a random effects model, in the eGFR and
albumin-to-creatinine ratio knots of most clinical interest (eGFR
45ml/min per 1.73m2 and albumin-to-creatinine ratio 30mg/g).
As possible sources of heterogeneity all variables listed in Table 1
were investigated, some being known risk factors for all-cause and
1350 Kidney International (2011) 79, 1341–1352
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cardiovascular mortality (for example, blood pressure, cholesterol,
and diabetes), others being effect modifiers (age and follow-up
duration).
In all analyses, a P-value o0.05 was considered to indicate
statistical significance.
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